These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34463922)

  • 1. Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant.
    Kale HP; Qureshi ZP; Shah R; Khandker R; Botteman M; Meng W; Benca R
    Adv Ther; 2021 Oct; 38(10):5221-5237. PubMed ID: 34463922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of suvorexant for the treatment of Japanese elderly patients with chronic insomnia in a virtual cohort.
    Nishimura S; Nakao M
    J Med Econ; 2018 Jul; 21(7):698-703. PubMed ID: 29667471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Falls, healthcare resources and costs in older adults with insomnia treated with zolpidem, trazodone, or benzodiazepines.
    Amari DT; Juday T; Frech FH; Wang W; Wu Z; Atkins N; Wickwire EM
    BMC Geriatr; 2022 Jun; 22(1):484. PubMed ID: 35658904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study.
    Kishi T; Sakuma K; Okuya M; Ninomiya K; Oya K; Kubo M; Matsui Y; Nomura I; Okuyama Y; Matsunaga S; Iwata N
    Neuropsychopharmacol Rep; 2019 Sep; 39(3):252-255. PubMed ID: 31283862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suvorexant for the Treatment of Insomnia in Adolescents.
    Kawabe K; Horiuchi F; Ochi M; Nishimoto K; Ueno SI; Oka Y
    J Child Adolesc Psychopharmacol; 2017 Nov; 27(9):792-795. PubMed ID: 28520464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
    Michelson D; Snyder E; Paradis E; Chengan-Liu M; Snavely DB; Hutzelmann J; Walsh JK; Krystal AD; Benca RM; Cohn M; Lines C; Roth T; Herring WJ
    Lancet Neurol; 2014 May; 13(5):461-71. PubMed ID: 24680372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.
    Kuriyama A; Tabata H
    Sleep Med Rev; 2017 Oct; 35():1-7. PubMed ID: 28365447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
    Snyder E; Ma J; Svetnik V; Connor KM; Lines C; Michelson D; Herring WJ
    Sleep Med; 2016 Mar; 19():93-100. PubMed ID: 27198953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare resource utilization and costs 2 years pre- and post-lumbar spine surgery for stenosis: a national claims cohort study of 22,182 cases.
    Koltsov JCB; Sambare TD; Alamin TF; Wood KB; Cheng I; Hu SS
    Spine J; 2022 Jun; 22(6):965-974. PubMed ID: 35123048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey.
    Sano H; Asai Y; Miyazaki M; Iwakura M; Maeda Y; Hara M
    Expert Opin Drug Saf; 2019 Nov; 18(11):1109-1118. PubMed ID: 31478753
    [No Abstract]   [Full Text] [Related]  

  • 13. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2014 Dec; 68(12):1429-41. PubMed ID: 25231363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental Healthcare Utilization and Cost Burden of Comorbid Insomnia in Alzheimer's Disease Patients.
    Qureshi ZP; Thiel E; Nelson J; Khandker R
    J Alzheimers Dis; 2021; 83(4):1679-1690. PubMed ID: 34420974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience.
    Matsumura T; Terada J; Yoshimura C; Koshikawa K; Kinoshita T; Yahaba M; Nagashima K; Sakao S; Tatsumi K
    Drug Des Devel Ther; 2019; 13():809-816. PubMed ID: 30880914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    Am J Geriatr Psychiatry; 2017 Jul; 25(7):791-802. PubMed ID: 28427826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
    Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
    Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Morin CM; Lines C; Michelson D
    Sleep Med; 2019 Apr; 56():219-223. PubMed ID: 30522875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
    Patel KV; Aspesi AV; Evoy KE
    Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental health care resource use and costs among adult patients with depression and treated for insomnia with zolpidem, trazodone, or benzodiazepines.
    Wickwire EM; Amari DT; Juday TR; Frech F; Gor D; Malhotra M
    Curr Med Res Opin; 2022 May; 38(5):711-720. PubMed ID: 35262444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.